SUZANNE LIND: Open Payments
NPI 1437250644 · NEW BRUNSWICK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,165 in 156 payments from 11 companies in 2025. Trend: 2023 $1,091 · 2024 $2,167 · 2025 $12,165
Speaker / faculty: $9,030Food & beverage: $3,135
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $9,701 |
| Alkermes, Inc. | 17 | $601 |
| Neurocrine BioSciences, Inc. | 23 | $546 |
| ABBVIE INC. | 22 | $371 |
| E.R. Squibb & Sons, L.L.C. | 21 | $330 |
| Janssen Pharmaceuticals, Inc | 15 | $201 |
| Luye Pharma (USA) Ltd. | 8 | $136 |
| Otsuka America Pharmaceutical, Inc. | 6 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $96 |
| Almatica Pharma LLC | 2 | $33 |
Products named: UZEDY, INGREZZA, ARISTADA, VRAYLAR, COBENFY, LYBALVI, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across NJ — which companies pay providers there.
